AZ and MedImmune get exclusive rights from Innate; deal expanded
AstraZeneca PLC and its biologics division MedImmune LLC licensed exclusive global rights to develop and sell a cancer therapy combining their MEDI4736 with Innate Pharma SA’s IPH2201. AZ also gets access to IPH2201 as a monotherapy and combo treatment in other undisclosed areas.
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.